Michael F Pintek Net Worth

The estimated Net Worth of Michael F Pintek is at least 2.11 百万$ dollars as of 13 September 2013. Michael Pintek owns over 3,000 units of Luminex Corp stock worth over 2,011,960$ and over the last 15 years Michael sold LMNX stock worth over 93,700$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Michael Pintek LMNX stock SEC Form 4 insiders trading

Michael has made over 2 trades of the Luminex Corp stock since 2010, according to the Form 4 filled with the SEC. Most recently Michael sold 3,000 units of LMNX stock worth 60,000$ on 13 September 2013.

The largest trade Michael's ever made was selling 3,000 units of Luminex Corp stock on 13 September 2013 worth over 60,000$. On average, Michael trades about 278 units every 57 days since 2009. As of 13 September 2013 Michael still owns at least 54,392 units of Luminex Corp stock.

You can see the complete history of Michael Pintek stock trades at the bottom of the page.

What's Michael Pintek's mailing address?

Michael's mailing address filed with the SEC is 12212 TECHNOLOGY BOULEVARD, , AUSTIN, TX, 78727.

Insiders trading at Luminex Corp

Over the last 21 years, insiders at Luminex Corp have traded over 55,627,864$ worth of Luminex Corp stock and bought 685,936 units worth 10,423,148$ . The most active insiders traders include G Walter Ii Loewenbaum、Douglas C Bryant、Laurence E Hirsch. On average, Luminex Corp executives and independent directors trade stock every 26 days with the average trade being worth of 888,944$. The most recent stock trade was executed by Harriss T Currie on 1 March 2021, trading 5,325 units of LMNX stock currently worth 97,235$.

What does Luminex Corp do?

The mission of Luminex is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. The Company offers a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. Luminex accelerates reliable answers while simplifying complexity and deliver certainty with a seamless experience.

Complete history of Michael Pintek stock trades at Luminex Corp

Luminex Corp executives and stock owners

Luminex Corp executives and other stock owners filed with the SEC include:

• Nachum Shamir,
  President, Chief Executive Officer, Director
• Harriss Currie,
  Chief Financial Officer, Senior Vice President - Finance, Treasurer
• Richard Rew,
  Senior Vice President, General Counsel and Corporate Secretary
• Todd Bennett,
  Senior Vice President - Global Sales and Customer Operations
• Randall Myers,
  Senior Vice President - Global Manufacturing and Quality
• Kenneth Samet,
  Independent Director
• Kevin McNamara,
  Independent Director
• Jimmy Kever,
  Independent Director
• Edward Ogunro,
  Lead Independent Director
• Thomas Erickson,
  Independent Director
• Stephen Eck,
  Independent Director
• Dijuana Lewis,
  Independent Director
• Eric Shapiro,
  Senior Vice President - Global Marketing
• Nancy Fairchild,
  Senior Vice President - Human Resources
• Chuck Collins,
  Senior Vice President - Research and Development
• Robert J Cresci,
  Director
• Tadd S. Lazarus,
  SVP, Chief Medical Officer
• Jay B Johnston,
  Director
• Russell S Bradley,
  VP, Strategic Planning and Bus
• G Walter Ii Loewenbaum,
  Director
• Jim D Kever,
  Director
• Gregory J Gosch,
  Vice President - Marketing
• Charles J. Collins,
  SR VP, R&D - US
• John C Carrano,
  VP, Research & Development
• J Stark Phd Thompson,
  Director
• Douglas C Bryant,
  EVP, Chief Operating Officer
• James W Jacobson,
  VP, Research & Development
• Oliver H Meek,
  VP, Manufacturing
• Randel S Martin,
  VP, Marketing/Sales
• Kristi M Richburg,
  Controller
• G Walter Ii Loewenbaum,
  Director
• C Thomas Caskey,
  Director
• Laurence E Hirsch,
  Director
• Fred C Jr Goad,
  Director
• Jeremy K Bridge Cook,
  VP, Luminex Molecular Diagn
• Michael F Pintek,
  SVP Operations
• Patrick J Balthrop,
  President, Chief Exec. Officer
• Timothy R Dehne,
  VP, Systems R&D
• David S Reiter,
  General Counsel & Secretary
• Gerard Vaillant,
  Director